Switzerland Jürg Utzinger, Director of the Swiss Tropical and Public Health Institute (Swiss TPH), addresses global health challenges, the significance of partnerships and the impact of new technologies on health outcomes. He states, “Our mission is to make the world a healthier place, focusing on topics such as climate change, infectious…
Switzerland Martine Ruggli discusses the evolving role of pharmacists in Switzerland’s healthcare system, addressing challenges and opportunities in digitalization, drug shortages, and regulatory reforms, as well as the need to leverage pharmacists’ expertise more broadly. Investing in and empowering pharmacists is essential for improving the quality, accessibility, and efficiency of…
Mexico Valney Suzuki highlights his focus on expanding access to Novo Nordisk’s innovations in Mexico, especially for vulnerable populations; the importance of ethical usage of the company’s groundbreaking semaglutide-based treatments for diabetes and obesity; and Mexico’s crucial role in Novo Nordisk’s global operations, not just as a market but also in…
Hong Kong Hong Kong’s ambitious plans to transform into an “innovation and technology” hub will require careful and deliberate combinations of Hong Kong and mainland capabilities. From this understanding, the idea for the Hong Kong-Shenzhen Innovation and Technology Park (HSITP) was born. This new science park on the border with Shenzhen is…
Switzerland Lucas Schalch of Intergenerika examines the challenges confronting Switzerland’s generic and biosimilar sectors, such as high production costs and changing regulations. Schalch underscores the importance of maintaining a favourable economic environment for these industries. We must work together to sustain a healthy and competitive market, ensuring that the generic…
Global Medtech-focused recruitment consultant Ivor Campbell casts his eye over the profiles the global medtech industry needs most today. Campbell argues that while specialist scientists and engineers remain as important as ever, medtech lacks leaders with the commercial acumen and results-driven mindset to turn innovation into profitable and sustainable ventures. …
Saudi Arabia Noncommunicable diseases are the leading cause of death and disability worldwide, accounting for 74 percent of all deaths and more than three out of four years lived with a disability. These chronic conditions – which cannot be transmitted from person to person and often require long-term or lifelong care –…
Hong Kong Chuen Yan Leung leads life science-focused venture capital firm Silver Dart Capital based out of Hong Kong and also serves as vice chairman of the Hong Kong Biotechnology Organization. In conversation, Leung outlines Silver Dart’s investments in growth-stage healthcare companies that are already scientifically de-risked and generating revenue; some of…
Switzerland Switzerland, home to industry giants like Novartis and Roche, boasts a thriving pharma industry that generates some seven percent of the country’s GDP, as well as a flourishing biotech scene. However, all is not so well in Switzerland’s domestic healthcare landscape, where surging insurance premiums and drug costs mean that…
Hong Kong Prof. Lo Chung-mau, Hong Kong’s Secretary for Health, delves into some of the key strategic initiatives for advancing Hong Kong’s healthcare and biomedical innovation. Key topics include the integration of the Greater Bay Area (GBA) for enhanced clinical trials, addressing the increasing needs of Hong Kong healthcare system, and leveraging…
Saudi Arabia Attracting, developing, and retaining talented workers – both Saudi and foreign – is perhaps the key sticking point to Saudi Arabia achieving its ambitious transformation targets. Thus far this has involved both ‘carrot’ and ‘stick’ initiatives, ranging from tax incentives and specialised training programs on one side, to mandatory ‘Saudization’…
Hong Kong One year since our last conversation, the Hong Kong Institute of Biotechnology’s Gina Jiang introduces the significant strides made in setting up a GMP facility for CAR-T cell therapy manufacturing at HKIB. Regulatory frameworks have now been developed to support clinical trials and the rollout of advanced therapies. Jiang highlights…
See our Cookie Privacy Policy Here